310 related articles for article (PubMed ID: 30859398)
21. Transformation of follicular lymphoma to plasmablastic lymphoma with c-myc gene rearrangement.
Ouansafi I; He B; Fraser C; Nie K; Mathew S; Bhanji R; Hoda R; Arabadjief M; Knowles D; Cerutti A; Orazi A; Tam W
Am J Clin Pathol; 2010 Dec; 134(6):972-81. PubMed ID: 21088162
[TBL] [Abstract][Full Text] [Related]
22. Achievement of the longest survival of paraneoplastic pemphigus with bronchiolitis obliterans associated with follicular lymphoma using R-CHOP chemotherapy.
Lee S; Yamauchi T; Ishii N; Hashimoto T; Kinoshita K; Imamura S; Kamiya K
Int J Hematol; 2017 Dec; 106(6):852-859. PubMed ID: 28791608
[TBL] [Abstract][Full Text] [Related]
23. Sequential therapy with alternating short courses of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) and R-FM (rituximab, fludarabine, mitoxantrone) followed by autologous stem cell transplantation results in long term remission in advanced follicular lymphoma.
Derenzini E; Casadei B; Broccoli A; Gandolfi L; Pellegrini C; Zinzani PL
Br J Haematol; 2014 Aug; 166(4):625-8. PubMed ID: 24750128
[No Abstract] [Full Text] [Related]
24. Doxorubicin-Based Chemotherapy and Radiation Therapy Produces Favorable Outcomes in Limited-Stage Plasmablastic Lymphoma: A Single-Institution Review.
Pinnix CC; Shah JJ; Chuang H; Costelloe CM; Medeiros LJ; Wogan CF; Reed V; Smith GL; Milgrom S; Patel K; Huo J; Turturro F; Romaguera J; Fayad L; Oki Y; Fanale MA; Westin J; Nastoupil L; Hagemeister FB; Rodriguez A; Qazilbash M; Shah N; Bashir Q; Ahmed S; Nieto Y; Hosing C; Rohren E; Dabaja B
Clin Lymphoma Myeloma Leuk; 2016 Mar; 16(3):122-8. PubMed ID: 26795083
[TBL] [Abstract][Full Text] [Related]
25. Plasmablastic transformation of a double hit follicular lymphoma: An emerging entity.
Khodaiji S; Mahajan V; Satyakam KS; Amare PSK
Indian J Pathol Microbiol; 2024 Apr; 67(2):411-414. PubMed ID: 38391382
[TBL] [Abstract][Full Text] [Related]
26. Extraoral plasmablastic lymphomas in a high human immunodeficiency virus endemic area.
Meer S; Perner Y; McAlpine ED; Willem P
Histopathology; 2020 Jan; 76(2):212-221. PubMed ID: 31361906
[TBL] [Abstract][Full Text] [Related]
27. Double-hit follicular lymphoma with MYC and BCL2 translocations: a study of 7 cases with a review of literature.
Miao Y; Hu S; Lu X; Li S; Wang W; Medeiros LJ; Lin P
Hum Pathol; 2016 Dec; 58():72-77. PubMed ID: 27544800
[TBL] [Abstract][Full Text] [Related]
28. Double hit B cell precursor leukemia/lymphoma in a patient with a prior diagnosis of follicular lymphoma: a diagnostic and therapeutic dilemma.
Bravo-Perez C; Pajares I; Muiña B; Escobar H; Amigo ML; Garcia-Malo MD; Garcia J; Rodriguez-Pinilla SM; Piris MA; Ortuño FJ
Ann Hematol; 2020 Feb; 99(2):391-393. PubMed ID: 31858188
[No Abstract] [Full Text] [Related]
29. Primary follicular large cell lymphoma of the testis in a child.
Lu D; Medeiros LJ; Eskenazi AE; Abruzzo LV
Arch Pathol Lab Med; 2001 Apr; 125(4):551-4. PubMed ID: 11260636
[TBL] [Abstract][Full Text] [Related]
30. A unique composite follicular lymphoma and mantle cell lymphoma with a mixed cell pattern and aggressive course.
Liu Y; Li P; Guo Y; Fan L; Wang L; Zhu J; Huang G; Yan Q; Wang Z
Am J Clin Pathol; 2014 May; 141(5):737-41. PubMed ID: 24713749
[TBL] [Abstract][Full Text] [Related]
31. Bendamustine plus Rituximab Versus R-CHOP as First-Line Treatment for Patients with Follicular Lymphoma Grade 3A: Evidence from a Multicenter, Retrospective Study.
Mondello P; Steiner N; Willenbacher W; Cerchione C; Nappi D; Mauro E; Ferrero S; Cuzzocrea S; Mian M
Oncologist; 2018 Apr; 23(4):454-460. PubMed ID: 29317554
[TBL] [Abstract][Full Text] [Related]
32. FcgammaRIIIA and FcgammaRIIA polymorphisms do not predict clinical outcome of follicular non-Hodgkin's lymphoma patients treated with sequential CHOP and rituximab.
Carlotti E; Palumbo GA; Oldani E; Tibullo D; Salmoiraghi S; Rossi A; Golay J; Pulsoni A; Foà R; Rambaldi A
Haematologica; 2007 Aug; 92(8):1127-30. PubMed ID: 17650444
[TBL] [Abstract][Full Text] [Related]
33. Outcomes after R-CHOP in patients with newly diagnosed advanced follicular lymphoma: a 10-year follow-up analysis of the JCOG0203 trial.
Watanabe T; Tobinai K; Wakabayashi M; Morishima Y; Kobayashi H; Kinoshita T; Suzuki T; Yamaguchi M; Ando K; Ogura M; Taniwaki M; Uike N; Yoshino T; Nawano S; Terauchi T; Hotta T; Nagai H; Tsukasaki K;
Lancet Haematol; 2018 Nov; 5(11):e520-e531. PubMed ID: 30389034
[TBL] [Abstract][Full Text] [Related]
34. ALK-positive diffuse large B-cell lymphoma: two more cases and a brief literature review.
Rudzki Z; Rucińska M; Jurczak W; Skotnicki AB; Maramorosz-Kurianowicz M; Mruk A; Piróg K; Utych G; Bodzioch P; Srebro-Stariczyk M; Włodarska I; Stachura J
Pol J Pathol; 2005; 56(1):37-45. PubMed ID: 15921012
[TBL] [Abstract][Full Text] [Related]
35. Distribution, function, and prognostic value of cytotoxic T lymphocytes in follicular lymphoma: a 3-D tissue-imaging study.
Laurent C; Müller S; Do C; Al-Saati T; Allart S; Larocca LM; Hohaus S; Duchez S; Quillet-Mary A; Laurent G; Brousset P; Valitutti S
Blood; 2011 Nov; 118(20):5371-9. PubMed ID: 21856865
[TBL] [Abstract][Full Text] [Related]
36. Solitary plasmablastic lymphoma in the esophagus.
Mihara K; Sasaki N; Mamoru O; Kanbe M; Ichinohe T; Suehiro S
Ann Hematol; 2016 Apr; 95(5):845-6. PubMed ID: 26925582
[No Abstract] [Full Text] [Related]
37. Real world data on young patients with high-risk diffuse large B-cell lymphoma treated with R-CHOP or R-CHOEP - MYC, BCL2 and BCL6 as prognostic biomarkers.
Pedersen MØ; Gang AO; Brown P; Pedersen M; Knudsen H; Nielsen SL; Poulsen T; Wirenfeldt Klausen T; Høgdall E; Nørgaard P
PLoS One; 2017; 12(10):e0186983. PubMed ID: 29088292
[TBL] [Abstract][Full Text] [Related]
38. [Follicular lymphoma complicated with myelofibrosis and macroglobulinemia at initial presentation].
Kuroda H; Abe T; Jomen W; Yoshida M; Matsuno T; Sato M; Yamada M; Sakurai T; Fujii S; Maeda M; Fujita M; Nagashima K; Murase K; Kato J
Rinsho Ketsueki; 2013 Nov; 54(11):2068-73. PubMed ID: 24305541
[TBL] [Abstract][Full Text] [Related]
39. Combined modality treatment for PET-positive non-Hodgkin lymphoma: favorable outcomes of combined modality treatment for patients with non-Hodgkin lymphoma and positive interim or postchemotherapy FDG-PET.
Halasz LM; Jacene HA; Catalano PJ; Van den Abbeele AD; Lacasce A; Mauch PM; Ng AK
Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):e647-54. PubMed ID: 22607911
[TBL] [Abstract][Full Text] [Related]
40. [Management of follicular lymphoma].
Izutsu K
Rinsho Ketsueki; 2014 Oct; 55(10):1929-36. PubMed ID: 25297757
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
